tarsons products completed the second tranche of an equity infusion totaling EUR 552,000 in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., on June 03, 2026. This investment is part of a total approved equity infusion of EUR 3,000,000. The funds will be utilized by the Singapore-based subsidiary for the repayment of its bank loan, payment of interest, and meeting general corporate purposes and operational requirements.

Pursuant to the investment, the company subscribed to 184 equity shares of Tarsons Life Science Pte. Ltd. at a nominal value of EUR 3,000 per share. The transaction was completed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary, incorporated on November 10, 2023, operates as a non-operating financial holding company and special purpose vehicle.

The first tranche of this investment, amounting to EUR 300,000, was completed on April 09, 2026, with the subscription of 100 equity shares. The latest tranche maintains the status of Tarsons Life Science Pte. Ltd. as a wholly-owned subsidiary of Tarsons Products, with no change in ownership percentage. The transaction is classified as a related party transaction conducted at arm’s length.

Investment Details

The following table outlines the specifics of the equity infusion:

Subsidiary Financials

Tarsons Life Science Pte. Ltd. has reported nil turnover since its incorporation. The financial performance for the past three fiscal years is detailed below:

The board of directors initially approved the total equity infusion of EUR 3,000,000 on February 06, 2026. Tarsons Products stated it will inform the stock exchanges regarding the completion of any subsequent tranches of the approved investment as they occur.

Tarsons Products has released the transcript of its earnings conference call held on May 25, 2026, detailing its financial performance for the quarter and financial year ended March 31, 2026. The company achieved its highest-ever quarterly revenue in Q4FY26, driven by strong domestic growth, although profitability was impacted by rising raw material costs and increased depreciation from recent capacity expansion. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Annual Financial Performance

For the financial year ended March 31, 2026, the company reported a consolidated net profit of ₹143.22 million, a decrease from ₹297.70 million in the previous year. Revenue from operations for the year rose to ₹4,225.13 million from ₹3,924.14 million in FY25. Total income for the year stood at ₹4,466.85 million, while total expenses increased to ₹4,236.59 million from ₹3,635.73 million in the prior year.

The following table summarizes the consolidated financial performance for the full year:

Q4 Performance

In the quarter ended March 31, 2026, Tarsons Products reported a notable contraction in profitability metrics on a year-on-year basis. The quarterly EBITDA stood at ₹341 million, compared to ₹369 million in the corresponding quarter of the previous year. The EBITDA margin for the quarter came in at 28.21%, down from 32.77% in the same period last year, reflecting increased cost pressures during the period. Net profit for the quarter fell to ₹42 million from ₹102 million, while revenue from operations rose to ₹1.21 billion from ₹1.13 billion on a year-on-year basis.

The following table presents the Q4 consolidated performance highlights:

Operational and Other Details

The company recorded an exceptional item regarding the statutory impact of new labour codes amounting to ₹11.27 million for the year. The Statutory Auditors, M/s. Price Waterhouse Chartered Accountants LLP, issued an unmodified opinion on the audited financial results. The board also noted that the trading window for designated persons will remain closed until 48 hours after the declaration of the financial results.

Management highlighted that the domestic business delivered strong growth of 11.7% year-on-year in Q4FY26, while exports declined by 13.4% due to geopolitical tensions and supply chain disruptions. The company expects its entire capex program to be fully commissioned during the first half of the current financial year, with depreciation projected to peak between ₹105 crore and ₹110 crore in FY27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE144Z01023/1b60c534cb1e4233.pdf